NCT03821233 - A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

September 27, 2024

Study Completion Date

October 8, 2024

Conditions

HER2-expressing Cancers

Interventions

DRUG

ZW49

"* Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study"

Trial Locations (16)

5042

Flinders Medical Centre, Adelaide

10065

Memorial Sloan Kettering Cancer Center, New York

13620

Seoul National University Bundang Hospital, Seongnam-si

19111

Fox Chase Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, PC, Fairfax

33612

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

60637

University of Chicago Medicine, Chicago

78229

NEXT Oncology, San Antonio

91010

City of Hope, Duarte

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H3T1E2

Jewish General Hospital, Montreal

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

All Listed Sponsors

lead

Zymeworks BC Inc.

INDUSTRY